News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Apr 23, 2018

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
Apr 18, 2018

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

Asset Transfer was Completed on April 12, 2018
- Photos 1
Apr 3, 2018

Astellas Named "Outstanding Employer" for Supporting Employees with Military Service
- Photos 1
Mar 28, 2018

Astellas Names Tatjana Dragovic, J.D. Head of Ethics & Compliance

Dragovic was previously Vice President, Ethics & Compliance Americas
- Photos 1
Mar 26, 2018

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 19, 2018

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC
Mar 15, 2018

Astellas Names Percival Barretto-Ko President, Americas Operations

Barretto-Ko was previously Senior Vice President, International Operations
- Photos 1
Mar 13, 2018

Astellas Announces Key Leadership Changes in Legal, Human Resources
- Photos 1
Feb 13, 2018

Astellas Acquires Universal Cells, Inc.

Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas
Feb 5, 2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Show per page